Faron Pharmaceuticals Ltd: Director/PCA Dealing

TURKU, FINLAND / ACCESS Newswire / June 30, 2025 /

Faron Pharmaceuticals Ltd. (AIM:FARN)(First North:FARON), a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, announces today that Dr Juho Jalkanen, Chief Executive Officer of the Company, acquired 22,127 ordinary shares in Faron at price of €2.26 per share on 27 June 2025. Following this purchase, Dr Jalkanen directly holds 1,112,015 ordinary shares in the Company, representing 0.99 per cent of the voting rights in the Company.

Additionally, Dr Juho Jalkanen acquired 2,000 ordinary shares in Faron at a price of 2.27 EUR per share on 27 June 2025 on behalf of his daughter.

Further details are set out in the Notification of Dealing Form below.

Director/PCA	Holding prior to purchase	Number of ordinary shares	Resultant interest in ordinary shares in the Company	Resultant percentage of voting rights in the Company
Juho Jalkanen	1,089,888	22,127	1,112,015	0.99%
Evelina Jalkanen*	Nil	2,000	2,000	0,00%

*Individuals deemed as a PCA to Juho Jalkanen

For more information, please contact:

IR Partners, Finland (Media) Riina Tuominen Kare Laukkanen	[phone] [e-mail] [phone] / [phone] [e-mail]
FINN Partners, US (Media) Alyssa Paldo	[phone] [e-mail]
Cairn Financial Advisers LLP (Nominated Adviser and Broker) Sandy Jamieson, Jo Turner	[phone]
Sisu Partners Oy (Certified Adviser on Nasdaq First North) Juha Karttunen Jukka Järvelä	[phone] [phone]

About bexmarilimab
Bexmarilimab is Faron's wholly owned, investigational immunotherapy designed to overcome resistance to existing treatments and optimize clinical outcomes, by targeting myeloid cell function and igniting the immune system. Bexmarilimab binds to Clever-1, an immunosuppressive receptor found on macrophages leading to tumor growth and metastases (i.e. helps cancer evade the immune system). By targeting the Clever-1 receptor on macrophages, bexmarilimab alters the tumor microenvironment, reprogramming macrophages from an immunosuppressive (M2) state to an immunostimulatory (M1) one, upregulating interferon production and priming the immune system to attack tumors and sensitizing cancer cells to standard of care.

About Faron Pharmaceuticals Ltd
Faron (AIM: FARN, First North: FARON) is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company's lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments. Further information is available at www.faron.com

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1	Details of the person discharging managerial responsibilities/person closely associated
a.	Name	a) Juho Jalkanen b) Eveliina Jalkanen
2	Reason for notification
a.	Position/Status	a) Chief Executive Officer b) PCA
b.	Initial notification/ Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name	Faron Pharmaceuticals Ltd.
b.	LEI	7437009H31TO1DC0EB42
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the financial instrument, type of instrument Identification Code	Ordinary Shares ISIN: FI4000153309
b.	Nature of the transaction	Purchase of ordinary shares
			Price(s) per share (p)	Volume(s)
			a) €2.26 b) €2.27	a) 22,127 b) 2,000
d.	Aggregated information Volume Price	Transaction details (a) (1): Volume 22,217 Unit price: 2.26 EUR Transaction details (b) (1): Volume 2,000 Unit price: 2.27 EUR
e.	Date of the transaction	27/06/2025
f.	Place of the transaction	Nasdaq First North Growth Market

SOURCE: Faron Pharmaceuticals

View the original press release on ACCESS Newswire:
https://www.accessnewswire.com/newsroom/en/biotechnology/faron-pharmaceuticals-ltd-director%2fpca-dealing-1044241